Ziekenhuis St Jansdal
- Address
- lock Available on a paid plan
Lung Cancer and Respiratory Research at Ziekenhuis St Jansdal
The Lung department at Ziekenhuis St Jansdal is a major center for clinical research in respiratory diseases and thoracic oncology. Much of the work focuses on non-small cell lung cancer, including advanced, metastatic, and early-stage disease, with studies designed to test new treatment strategies and improve outcomes after surgery or radiation.
- Research in lung cancer, especially non-small cell lung cancer with EGFR, KRAS G12C, RET, and PD-L1-related subgroups
- Studies in small-cell lung cancer and refractory chronic cough
- Trials evaluating new combinations to improve survival, disease control, and treatment response
- Work on better approaches after surgery, radiation, or prior treatment failure
This research landscape highlights a strong focus on developing more effective and personalized options for people with lung cancer and related airway conditions.
Cardiovascular and Metabolic Studies
Clinical trials at the site also cover cardiovascular diseases and nutritional and metabolic disorders. These studies include people at high risk of heart events, as well as patients with heart failure, myocardial infarction, atherosclerotic cardiovascular disease, chronic kidney disease, obesity, and elevated lipoprotein(a), with the goal of preventing complications and improving long-term heart and kidney health.
- Prevention of heart attack, stroke, and other major cardiovascular events
- Research in heart failure after myocardial infarction and in high-risk patients
- Studies linking kidney disease, inflammation, and cardiovascular risk
- Trials testing new ways to reduce metabolic and vascular complications
These studies reflect a broad effort to improve prevention and treatment for people facing overlapping cardiometabolic risks.
Hematology and Blood Cancer Research
The site is active in hemic and lymphatic diseases, with trials in chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and multiple myeloma. The main aim is to refine treatment choices, improve disease control, and reduce treatment-related burden in blood cancers.
- Studies in CLL and SLL focused on better disease control and treatment tailoring
- Research in DLBCL aimed at protecting the heart during cancer therapy
- Trials in multiple myeloma exploring treatment-free intervals and long-term management
- Evaluation of new combinations for deeper and more durable responses
This area emphasizes more personalized care for patients with blood cancers, balancing effectiveness with quality of life.
Breast, Gynecologic, and Digestive Cancer Trials
Research also extends into neoplasms affecting the breast, female reproductive system, and digestive tract. Trials include breast cancer, triple negative breast cancer, vulvar high-grade squamous intraepithelial lesion, colorectal cancer, and gastric cancer, with studies focused on improving recurrence prevention, comparing treatment strategies, and strengthening disease control.
- Trials in breast cancer testing adjuvant and first-line treatment strategies
- Research in triple negative breast cancer aimed at improving outcomes after initial therapy
- Studies in vulvar disease looking at recurrence prevention
- Digestive cancer research in colorectal and gastric cancer focused on survival and treatment effectiveness
This portfolio shows a strong interest in improving care across several challenging cancer types through more effective and better-targeted treatment approaches.
Inflammatory, Autoimmune, and Respiratory Disease Research
The site participates in studies on musculoskeletal diseases and respiratory tract diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, polymyalgia rheumatica, chronic obstructive pulmonary disease, severe asthma, and chronic cough. These trials aim to improve symptom control, reduce flare-ups, and find better long-term management options.
- Inflammatory disease studies in rheumatology focused on disease activity and treatment adjustment
- Research in polymyalgia rheumatica and related conditions to improve symptom control
- Trials in COPD, asthma, and chronic cough testing new ways to reduce symptoms and exacerbations
- Work to support more stable long-term care for chronic inflammatory and airway diseases
Overall, this area reflects a practical focus on relieving symptoms and improving daily function in chronic inflammatory and respiratory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 123 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 122 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ziekenhuis St Jansdal
lock Showing 1 of 59 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 123 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 12 | Unknown | 2013-10-10 | 2025-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.